|
Market Closed -
Euronext Bruxelles
00:55:00 21/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 279.60 EUR | -1.27% |
|
-5.70% | +17.18% |
| 11-19 | AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco | RE |
| 11-19 | US FDA approves Regeneron's drug for generalized myasthenia gravis (November 18) | RE |
| Market Cap | 53.31B 58.53B 49.12B 44.68B 83.83B 5,420B 88.1B 598B 238B 2,960B 220B 215B 9,291B | P/E 2026 * |
23.5x | P/E 2027 * | 20.5x |
|---|---|---|---|---|---|
| Enterprise Value | 53.4B 58.63B 49.2B 44.76B 83.96B 5,429B 88.24B 599B 238B 2,965B 220B 215B 9,306B | EV / Sales 2026 * |
5.87x | EV / Sales 2027 * | 5.05x |
| Free-Float |
61.59% | Yield 2026 * |
0.52% | Yield 2027 * | 0.54% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
| UCB | Real-time | ||
| UNC | Delayed | ||
| UNC | Delayed | ||
| UNC | Real-time | ||
| UNC | Delayed | ||
| UCBJF | Delayed | ||
| 0NZT | Delayed | ||
| UNC | Real-time | ||
| 0NZT | Real-time | ||
| UCB | End-of-day quote | ||
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | -1.27% | ||
| 1 week | -5.70% | ||
| Current month | -0.64% | ||
| 1 month | +27.67% | ||
| 3 months | +28.32% | ||
| 6 months | +17.18% | ||
| Current year | +17.18% |
| 1 week | 277.4 | 299 | |
| 1 month | 230.1 | 301.2 | |
| Current year | 197.45 | 301.2 | |
| 1 year | 197.45 | 301.2 | |
| 3 years | 67.08 | 301.2 | |
| 5 years | 65.4 | 301.2 | |
| 10 years | 54.84 | 301.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/1/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/1/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/1/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.27% | -5.70% | +21.78% | +309.49% | 58.53B | ||
| -0.30% | -6.68% | +29.12% | +125.42% | 1,200B | ||
| +1.25% | -5.35% | +33.19% | +80.42% | 651B | ||
| +0.94% | -2.99% | +24.73% | +106.93% | 506B | ||
| -0.60% | -1.95% | +27.26% | +67.32% | 377B | ||
| +0.69% | -9.50% | +40.80% | +30.23% | 330B | ||
| +0.41% | -4.70% | +27.23% | +51.59% | 288B | ||
| +0.81% | -4.08% | -1.74% | +32.71% | 272B | ||
| -0.15% | -6.45% | +29.63% | +64.18% | 236B | ||
| -0.06% | -0.98% | +33.15% | +118.99% | 206B | ||
| Average | +0.20% | -4.85% | +26.51% | +98.73% | 412B | |
| Weighted average by Cap. | +0.37% | -5.20% | +27.94% | +90.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.1B 9.99B 8.39B 7.63B 14.31B 925B 15.04B 102B 40.56B 505B 37.49B 36.7B 1,586B | 10.1B 11.09B 9.31B 8.47B 15.88B 1,027B 16.69B 113B 45.02B 561B 41.6B 40.73B 1,760B |
| Net income | 2.31B 2.54B 2.13B 1.94B 3.63B 235B 3.82B 25.92B 10.3B 128B 9.52B 9.32B 403B | 2.64B 2.9B 2.43B 2.21B 4.15B 268B 4.36B 29.58B 11.76B 146B 10.86B 10.64B 460B |
| Net Debt | 87.29M 95.84M 80.44M 73.17M 137M 8.87B 144M 979M 389M 4.85B 360M 352M 15.21B | -2.27B -2.49B -2.09B -1.9B -3.57B -231B -3.76B -25.48B -10.13B -126B -9.36B -9.16B -396B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | €279.60 | -1.27% | 252,719 |
| 19/11/26 | €283.20 | -0.67% | 203,780 |
| 18/11/26 | €285.10 | -0.59% | 235,516 |
| 17/11/26 | €286.80 | -2.81% | 303,415 |
| 16/11/26 | €295.10 | -0.47% | 195,366 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions




















